GlaxoSmithKline Q1 Profit, Sales Decline As COVID-19 Vaccination Delay Other Treatments; Backs 2021 Outlook

First up is the Immunocore-partnered GSK3537142 (NYESO-ImmTAC), an anti-CD3 bispecific targeting NY-ESO, testing in solid tumors and synovial sarcoma.

It also culled Duchenne muscular dystrophy hopeful in GSK3439171, which worked as a hematopoietic prostaglandin D2 synthase inhibitor. 

See the Q1 earnings presentation here.

Price Action: GSK shares are up 0.11% at $37.77 on the last check Wednesday.


1 2
View single page >> |

© 2021 Benzinga does not provide investment advice. All rights reserved.

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.